Table 3 Cox regression analysis of SRD5A3 and other clinicopathological factors in BC patients
From: Over-expression of SRD5A3 and its prognostic significance in breast cancer
Covariates | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
HR | 95% CI | P-value | HR | 95% CI | P-value | ||
Age | 1.018 | 1.005–1.030 | 0.004 | 1.039 | 1.020–1.059 | < 0.001 | |
Gender female | 0.429 | 0.136–1.349 | 0.148 | 1.137 | 0.258–5.010 | 0.866 | |
Stage 2 | NA | NA | NA | 1.268 | 0.000–4.583E+ 43 | 0.996 | |
Stage 3 | 68.847 | 17.534–270.327 | < 0.001 | 211,065.668 | 0.000–1.280E+ 43 | 0.782 | |
Stage 4 | 823,685.985 | 0.000–2.511E+ 72 | 0.862 | 184,003.037 | 0.000–1.125E+ 43 | 0.785 | |
HER2 + | 0.468 | 0.115–1.907 | 0.289 | 0.264 | 0.063 | 1.101 | 0.068 |
Triple-negative | 0.327 | 0.132–0.810 | 0.016 | 0.545 | 0.217 | 1.366 | 0.195 |
SRD5A3 | 1.000 | 1.000–1.000 | 0.014 | 1.865 | 1.129 | 3.081 | 0.015 |